161 related articles for article (PubMed ID: 36139570)
1. Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients.
Gambichler T; Stang A; Mansour R; Scheel CH; Nick C; Abu Rached N; Becker JC; Susok L
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139570
[TBL] [Abstract][Full Text] [Related]
2. The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.
Fucà G; Beninato T; Bini M; Mazzeo L; Di Guardo L; Cimminiello C; Randon G; Apollonio G; Bisogno I; Del Vecchio M; Lauria Pantano C; Di Nicola M; de Braud F; Del Vecchio M
Target Oncol; 2021 Jul; 16(4):529-536. PubMed ID: 34076798
[TBL] [Abstract][Full Text] [Related]
3. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
Provenzano L; Lobefaro R; Ligorio F; Zattarin E; Zambelli L; Sposetti C; Presti D; Montelatici G; Ficchì A; Martinetti A; Arata A; Del Vecchio M; Lauria Pantano C; Formisano B; Bianchi GV; Capri G; de Braud F; Vernieri C; Fucà G
Ther Adv Med Oncol; 2023; 15():17588359231165978. PubMed ID: 37063779
[TBL] [Abstract][Full Text] [Related]
4. Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma.
Gambichler T; Said S; Abu Rached N; Scheel CH; Susok L; Stranzenbach R; Becker JC
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3183-3189. PubMed ID: 35098389
[TBL] [Abstract][Full Text] [Related]
5. The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy.
Susok L; Said S; Reinert D; Mansour R; Scheel CH; Becker JC; Gambichler T
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3103-3108. PubMed ID: 35006344
[TBL] [Abstract][Full Text] [Related]
6. The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery.
Sato S; Shimizu T; Ishizuka M; Suda K; Shibuya N; Hachiya H; Iso Y; Takagi K; Aoki T; Kubota K
Surg Today; 2022 Aug; 52(8):1160-1169. PubMed ID: 35015151
[TBL] [Abstract][Full Text] [Related]
7. Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma.
Su Z; Tang J; He Y; Zeng WH; Yu Q; Cao XL; Zou GR
Oncol Lett; 2024 Jun; 27(6):252. PubMed ID: 38646495
[TBL] [Abstract][Full Text] [Related]
8. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
9. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
10. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Fucà G; Guarini V; Antoniotti C; Morano F; Moretto R; Corallo S; Marmorino F; Lonardi S; Rimassa L; Sartore-Bianchi A; Borelli B; Tampellini M; Bustreo S; Claravezza M; Boccaccino A; Murialdo R; Zaniboni A; Tomasello G; Loupakis F; Adamo V; Tonini G; Cortesi E; de Braud F; Cremolini C; Pietrantonio F
Br J Cancer; 2020 Aug; 123(3):403-409. PubMed ID: 32424148
[TBL] [Abstract][Full Text] [Related]
11. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
Zaragoza J; Caille A; Beneton N; Bens G; Christiann F; Maillard H; Machet L
Br J Dermatol; 2016 Jan; 174(1):146-51. PubMed ID: 26343230
[TBL] [Abstract][Full Text] [Related]
12. Early inflammatory biomarkers and melanoma survival.
Fortes C; Mastroeni S; Zappalà AR; Passarelli F; Ricci F; Abeni D; Michelozzi P
Int J Dermatol; 2023 Jun; 62(6):752-758. PubMed ID: 36872079
[TBL] [Abstract][Full Text] [Related]
13. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
14. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of neutrophil-lymphocyte ratio is superior to derived neutrophil-lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up.
Jin H; Sun J; Zhu K; Liu X; Zhang Q; Shen Q; Gao Y; Yu J
Onco Targets Ther; 2017; 10():2655-2664. PubMed ID: 28579803
[TBL] [Abstract][Full Text] [Related]
16. Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study.
Wade RG; Robinson AV; Lo MCI; Keeble C; Marples M; Dewar DJ; Moncrieff MDS; Peach H
Ann Surg Oncol; 2018 Oct; 25(11):3341-3349. PubMed ID: 30066226
[TBL] [Abstract][Full Text] [Related]
17. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
19. Pretreatment Neutrophil-to-Lymphocyte Ratio: A Prognostic Biomarker of Survival in Patients With Epithelial Ovarian Cancer.
John-Olabode SO; Okunade KS; Olorunfemi G; Soibi-Harry A; Rimi G; Osunwusi B; Okunowo A; Amaeshi L; Anorlu R
Cureus; 2021 Jul; 13(7):e16429. PubMed ID: 34422466
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
[Next] [New Search]